Đánh giá kết quả điều trị ung thư tuyến giáp không biệt hóa tại Bệnh viện K

To evaluate the treatment outcomes of anaplastic thyroid cancer at the national cancer hospital. Method: a retrospective study was conducted among 31 patients with anaplastic thyroid cancer who were treated at the National cancer hospital from January 2011 to December 2021. Results: The median survival time was 6.9 months, and the 2-year overall survival rate was 12.1%. There was a clear difference in survival time between the factors. Specifically, the overall survival time rate in stage IVA was 33.3% while all patients died in stage IVB, and stage IVC (p = 0.00). The rate in the group of patients with surgery was 16.6%, but in the group of patients without surgery, this figure was equal to zero (p = 0.00). Although the 2-year survival rate of patients having tumors with a size less than 6cm was 27.8%, all patients having tumors with a size ≥ 6cm were fatal (p = 0.009). For no lymph node metastasis patients, the rate was 33.3% while all lymph node metastasis patients were fatal (p = 0.00). Females were 18.1% while all males died, p = 0.00. Surgery combined with chemotherapy gave the best survival rate with 21.8%, p = 0.00. Conclusions: The poor overall survival of all anaplastic thyroid cancer patients. Multimodality treatment for aplastic thyroid cancer improves overall survival. Male, tumor ≥ 6cm, without surgery, lymph node metastasis are factors affecting overall survival time.